Recent

% | $
Quotes you view appear here for quick access.

NeuroMetrix Inc. Message Board

bernsteinjoshi 23 posts  |  Last Activity: Jul 21, 2015 10:27 AM Member since: Jun 12, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • bernsteinjoshi bernsteinjoshi Jul 21, 2015 10:27 AM Flag

    you hit the nail

    Sentiment: Strong Sell

  • thats the numbers from USA and most European Countries . And there is only 1-2% of Worldwide Institutional Money in precious metal market, the most money is invested in the Bond Market 50% and Stock Market 48% .

    So how should the Goldprice benefit when most investors put their money in unbacked papergold which they increase endless ? The Banksters created these Ponzi Schemes because they are the only one who benefit on multiple ways .

    Again the only way to help the Goldprice is to buy PHYSICAL Gold NOT worthless Papergold .Think about it guys .

    Sentiment: Strong Sell

  • so if you wants higher Gold price then stay away from such Ponzi Schemes ETF´s and buy it in Physical form . Papergold like this GLD is created by the Banksters to steal your money and to use it for the Manipulation of Gold its a Win Win Situation for the Banksters . In short if you invest in such Ponzi Schemes then you helping the Banksters indirectly on the Gold Price Manipulation . Think about it guys !
    --

    Sentiment: Strong Sell

  • bernsteinjoshi bernsteinjoshi Jun 15, 2015 7:56 AM Flag

    Good News out today and much more to come ...

    Sentiment: Strong Buy

  • before its to late and stay away from this GLD garbage .

    10:06p ET Tuesday, July 9, 2015

    Recent reports from the U.S. Commodity Futures Trading Commission and the CME Group, operator of the New York Commodity Exchange, indicate that JPMorganChase & Co. is administering the Federal Reserve's gold swapping and lending operations and that for the time being the exchange's gold contracts are being guaranteed by the U.S. government.

    That analysis is published today by Colorado securities lawyer Avery B. Goodman, who draws heavily on GATA's documentation of U.S. government intervention in the gold market.

    Goodman's conclusion arises largely from the unnecessarily disproportionate assignment to JPMorganChase of Comex gold deliveries, as recorded in the CFTC's June 2 bank participation report for gold futures. Essentially, Goodman writes, last month the Fed rescued the Comex from a gold delivery deficiency, but the U.S. gold reserve, now guaranteeing the Comex, will not last forever.

    Goodman's may prove to be the most important analysis written about the gold "market" this year. If they meant to provide the world with any serious journalism, mainstream financial news organizations quickly would put questions about Goodman's analysis to the Federal Reserve, CME Group, and JPMorgan Chase.

    Goodman's analysis is headlined "Did Comex Just Receive A Physical Gold Bailout from the Fed?" GOOGLE IT yahoo dont let me post links .

    Sentiment: Strong Sell

  • Reply to

    What's next?

    by pardionman Jun 9, 2015 3:07 AM
    bernsteinjoshi bernsteinjoshi Jun 9, 2015 8:26 AM Flag

    Your shares will be changed to new Company Aralez shares IF you dont sell before the completion of the deal by 4Q .

    At closing, each share of POZEN common stock will be converted into the right to receive one Aralez ordinary share and each common share of Tribute (other than dissenting shares) will be exchanged for 0.1455 Aralez ordinary shares. As a result of the proposed transaction and before giving effect to the contemplated financing, stockholders of POZEN will own approximately 66 percent of Aralez and shareholders of Tribute would own approximately 34 percent of Aralez, in each case prior to giving effect to any exercise of any outstanding options or warrants or vesting and delivery of any restricted stock units of either company after the date hereof

  • GSK acquired Reliant for $1.3 Billion in 2007 . The Management of MTNB are definitely one of the best in the DYSLIPIDEMIA area thats for sure.

    They are still on track to submit US-NDA for the Drug (Mat9001) in 2017 . The newly acquired Drug Mat2203 is another promising Drug which is Phase 2 .

    MTNB is very cheap and has a fantastic Management .Its definitely a better Opportunity than the massive overpriced Amarin whatever the Basher here are tried to tell you .

    Sentiment: Strong Buy

  • Reply to

    Can someone explain the licensing model?

    by itrizia May 20, 2015 7:36 PM
    bernsteinjoshi bernsteinjoshi May 21, 2015 8:54 AM Flag

    "So how come multiple P3s and MAAs don't cost 50mil/qrtr?"

    The Company operates in a lean, fully outsourced business model that allows a limited burn rate.Redhill has agreement with contract research organization (CRO) who performing the clinical trials for them thats how they save a lot of money .

    A contract research organization (CRO) is an organization that provides support to the pharmaceutical, biotechnology, and medical device industries in the form of research services outsourced on a contract basis. A CRO may provide such services as biopharmaceutical development, biologic assay development, commercialization, preclinical research, clinical research, clinical trials management, and pharmacovigilance. CROs also support foundations, research institutions, and universities, in addition to governmental organizations (such as the NIH, EMA, etc.).[

    Many CROs specifically provide clinical-study and clinical-trial support for drugs and/or medical devices.CROs range from large, international full-service organizations to small, niche specialty groups.

    CROs that specialize in clinical-trials services can offer their clients the expertise of moving a new drug or device from its conception to FDA/EMA marketing approval, without the drug sponsor having to maintain a staff for these services.

    Sentiment: Strong Buy

  • Reply to

    Crohns disease; what's the cause?

    by itrizia May 19, 2015 6:04 PM
    bernsteinjoshi bernsteinjoshi May 20, 2015 1:43 AM Flag

    "Our drug cocktail has some VERY serous side effects. It turns the skin pink, and the antibiotics are harsh too. Nasty enough for pfizer to drop the drug."

    Yes but there was progress since that time they improved the Drug and finished a Safety Study with positive results .Looks like the Drug works better than current blockbuster and standard of care Remicade .

    RHB-104 (Crohn’s) -Progress Since Australian Phase III (Pfizer) Study

    •Improved formulation -all-in-one capsule

    •Initiated PK program, conducted a Phase I safety study, a food effect study and a drug-drug interaction
    (DDI) study, and initiated Population-PK study

    Preliminary positive safety results in a Phase I study (2014)

    RHB-104 (Crohn’s) -80% Remission in Pediatric Study Presented at ACG in October 2013

    --
    High hopes for a Crohn's disease cure

    The drug company RedHill Biopharma, has licensed Naser’s DNA technology for detecting the bacteria associated with Crohn's disease, known as Mycobacterium avium subspecies paratuberculosis - or MAP, which Naser believes is the cause of the disease

    Naser however says he has seen cases where people's lives have been completely restored following the treatment that is an anti-MAP antibiotic regimen known as RHB 104.

    Naser says the drug regimen is different than current treatments with drugs because it addresses the problem rather than the symptoms

  • Reply to

    Roth's valuation of RHB-105?

    by storysniffa May 9, 2015 7:03 PM
    bernsteinjoshi bernsteinjoshi May 19, 2015 3:26 PM Flag

    Celladon is a one trick pony scam so its no surprise that it drops like a rock .

    Redhill has lots of irons in the fire ( 9 Drugs in late stage ) some in Phase 3 and some already under review by FDA and EU . Redhill is a relative safe play compared to most Biotechs .

  • This undiscovered Sleeping Giant could move like ESPR or BLUE because of its extremly low float . Redhill is the best Biotech you can get for this ridiculous low Market Cap of $160 Million,GL

    Results from Phase 3 of Blockbuster Candidate RHB 105 (H. pylori ) coming IN JUNE ..(Market Size: U.S. market is estimated at approximately $1-1.5 billion)

    Results from Phase 3 of Bekinda (gastroenteritis and gastritis) in 2H 2015 ..(Worldwide potential market could exceed $650 million annually)

    RHB-104: Top-line interim results from Phase IIa study for Multiple Sclerosis in 2H 2015 ..(Market Size: Worldwide market of over $14 billion)

    EU Approval for Rizaport (Mirgaine) expected for 2H 2015 ..(The target market for RIZAPORT™, estimated at approximately $870 million)

    EU Approval for Bekinda (oncology support) expected for 2H 2015 ..(Worldwide market for serotonin (5-HT3) receptor inhibitors is estimated at $900 million)

    Sentiment: Strong Buy

  • WSA: Certainly, and perhaps you can walk us through your background and experience and talk a little bit about some of the key management over at RedHill.

    Dror Ben-Asher: First Juan, look at our website, there’s the presentation there on slide seven. We listed not only our executive management but also the board of directors and advisory board as well. And there, one sees prominent names such as Dan Suesskind on our Board of Directors. Dan has been with Teva Pharmaceuticals for over 30 years as CFO and Director, and one of the very few people who made Teva what it is, from a very small local player in Israel in the 80’s to what it is today, the pharma giant that Teva is today. And Dan is a strong believer in RedHill and an investor as well.

    Another director that I would like to mention is Dr. Cabilly. Shmuel Cabilly is a scientist who invented a couple of very important patents called Cabilly 1 and Cabilly 2, and those are the underlying basic patents of the application of monoclonal antibodies to therapeutics. His technology currently underlies probably 30 drugs on the market selling in total dozens of billions of dollars including Remicade, Humira and many others. And Cabilly is one of our largest investors as well.

    On our Advisory Board, I will mention a couple of names – Dr. Jeff Leighton, Professor Chezy Barenholz and Dr. Werner Tschollar. Those are world-renown experts in science and pharma research coming from Novartis and Glaxo and so on. So we have a very strong board of directors and a very strong advisory board as well.

    And then, as far as the RedHill management, there’s only 20 people. Most of R&D is in North America. Among those people there are people who have brought several drugs to the US market and a total hundreds of years of cumulative experience in bringing drugs to the US Market.

    Sentiment: Strong Buy

  • bernsteinjoshi bernsteinjoshi May 18, 2015 8:13 AM Flag

    They have Cash until December so it could be enough to get a Partnerdeal done before running our of cash .

    Cash balance at March 31 = $9.7 Million
    Debt payments= $2.6 Million
    additional cash to be received in Oktober= $600k

    Cash Balance after the numbers above = $7.7 Million
    Burn-Rate $900K per Month

    They have 8+ Months of Cash so its enough until December .

    The company's cash and near-term receivables at March 31, 2015, together with current proceeds from the exercise of warrants, totalled $9.7-million that will be available to finance continuing obligations. The company estimates that, based on the expected monthly burn rate of approximately $900,000 and scheduled debt payments of $2.6-million, it continues to have the required liquidity to finance its operations and financial obligations into the fourth quarter of calendar 2015

    In addition, following quarter-end, Telesta received its first payment of $600,000 from an indemnification holdback also related to the sale of this division, with an additional $600,000 to be received in October, 2015.

    Sentiment: Strong Buy

  • Reply to

    Roth's valuation of RHB-105?

    by storysniffa May 9, 2015 7:03 PM
    bernsteinjoshi bernsteinjoshi May 15, 2015 9:48 PM Flag

    "Their drugs are bought from others who for some reason did not want them."

    completely wrong they bought these Drugs from Biotechs who were close to Bankruptcy thats a big difference.
    I was invested in Teva and Taro both are isreali Stocks who are very successful to date . You should do your own DD better then you will have higher chance to make money .

    They have a fantastic Management thats one of the reason for my investment here

    WSA: Certainly, and perhaps you can walk us through your background and experience and talk a little bit about some of the key management over at RedHill.

    Dror Ben-Asher: First Juan, look at our website, there’s the presentation there on slide seven. We listed not only our executive management but also the board of directors and advisory board as well. And there, one sees prominent names such as Dan Suesskind on our Board of Directors. Dan has been with Teva Pharmaceuticals for over 30 years as CFO and Director, and one of the very few people who made Teva what it is, from a very small local player in Israel in the 80’s to what it is today, the pharma giant that Teva is today. And Dan is a strong believer in RedHill and an investor as well.

    Another director that I would like to mention is Dr. Cabilly. Shmuel Cabilly is a scientist who invented a couple of very important patents called Cabilly 1 and Cabilly 2, and those are the underlying basic patents of the application of monoclonal antibodies to therapeutics. His technology currently underlies probably 30 drugs on the market selling in total dozens of billions of dollars including Remicade, Humira and many others. And Cabilly is one of our largest investors as well.

    On our Advisory Board, I will mention a couple of names – Dr. Jeff Leighton, Professor Chezy Barenholz and Dr. Werner Tschollar. Those are world-renown experts in science and pharma research coming from Novartis and Glaxo and so on. So we have a very strong board of directors and a very strong advisory board as well.

    Sentiment: Strong Buy

  • bernsteinjoshi bernsteinjoshi May 14, 2015 9:28 AM Flag

    BEKINDA™ (RHB-102): Oncology Support -MAA Submitted in Europe / Pre-NDA in the U.S.

    Planned Indication: Prevention of chemotherapy and radiotherapy-induced nausea and vomiting
    Drug:Patent-protected, once-daily extended release oral tablet ondansetron (Zofran®)
    Potential Advantages:Significantly superior patient compliance improves ability to withstand treatment thus increasing adherence to chemotherapy/radiotherapy*The only once-daily oral formulation of ondansetron, likely to be the first to reach U.S. market
    Market Size:WW market for serotonin (5-HT3) receptor inhibitors estimated to exceed $940 million in 2014

    European marketing application (MAA) submitted to the UK MHRA Dec. 2014 -regulatory feedback expected in H2/2015

  • These two Drugs alone will push Redhill into profitability if approved which is highly likely .

    RIZAPORT™ (RHB-103) for Migraines -Commercial Triptan Market Opportunity

    •RIZAPORT™ likely to be the first thin film triptan to reach the U.S. market
    •Rizatriptan was selected as the drug to deliver via VersaFilm™ because it:

    1.Exhibits the highest efficacy data compared to all triptans
    2.Exhibits the shortest Tmax, indicating rapid onset of action, which is extremely important for migraine sufferers
    3.Highly effective in treatment of migraine attacks in children and adolescents. This sub-group
    together with the elderly could greatly benefit from RIZAPORT™

    The worldwide market for anti-migraine drugs was estimated to reach approximately $
    1.9 billion in 2014, of which the sales of triptan drugs, the target market for RIZAPORT™, were estimated at
    approximately $870 million

    A survey of physicians who treat migraine headaches was conducted and showed that a large
    majority of these would prescribe a film based migraine treatment

    European marketing application (MAA) filed October 2014 under the brand name RIZAPORT™,
    BfArM potential feedback regarding the MAA expected during H2/2015

    to be continued...

    Sentiment: Strong Buy

  • Reply to

    Is Eradicate the first Ph3?

    by stock_lurker May 13, 2015 7:09 PM
    bernsteinjoshi bernsteinjoshi May 14, 2015 1:02 AM Flag

    A Second Phase 3 Confirmatory Study is in most cases required to file the NDA thats nothing new in the Biotech area . If the first Phase 3 is positive then the stock will explode because we will know that the drug works . Another Phase 3 Study will take just around 15 months untill we get results like the first Phase 3 .

    They have another Drug called Bekinda with Phase 3 results coming in 2H 2015 if positive then they can file directly marketing applications in the U.S. and Europe .Worldwide potential market could exceed $650 million annually.

    And 2 EU approvals expected in 4Q 2015 for their Migraine and Oncology support Drugs .

    They have $33 Million in Cash and a burn-rate of around $3.5 Million per Quarter or over 2 years could be enough to reach profitability .The Market Cap of $155 Million is dirt low for a Biotech with such a Late Stage Pipeline .

    You see there is a lot of reasons to own this massive undervalued stock .

    Cash Balance1 as of March 31, 2015 was approximately $32.5 million, compared to $22.9 million for the year ended December 31, 2014. The increase resulted mainly from the closing of the underwritten public offering of approximately $14.4 million in February 2015.

    Sentiment: Strong Buy

  • because the Drug was successful in Phase 2 in 130 Patients there are only 120 patients in current Phase 3 Study .

    RHB-105 Phase II Showed 90% Efficacy

    The study (concluded 2005) was designed to test the efficacy of a triple therapy regimen
    combining rifabutin, pantoprazole and amoxicillin as rescue therapy for patients in whom eradication of
    H. pylori had failed standard clarithromycin-based triple therapy*

    Study Description Prospective, two-arm, Phase II study in Australia
    Number of Subjects 130

    H. pylori Infection -A Growing Concern

    •H. pyloribacteria plays critical role in gastritis peptic ulcer and gastric cancer
    •Prevalence of H. pylori infection in the U.S.is estimated at 30-40% of the population
    -over 100 million people*, with three million treated patients

    Standard therapy fails in over 20% of patients who remain H. pylori positive due to
    growing resistance of H. pylori to clarithromycin and metronidazole
    -antibiotics commonly used in standard combination therapies

    •Nov. 2014 FDA granted QIDP designation to RHB-105 under the GAIN Act, allowing for Fast-Track status with an expedited development pathway and Priority Review status providing for a shortened review time of a future potential marketing application

    •If approved, RHB-105 will receive an additional five years of U.S. market exclusivity on
    top of the standard exclusivity period

    Sentiment: Strong Buy

  • Reply to

    institutional ownership

    by madetotroll May 11, 2015 1:46 PM
    bernsteinjoshi bernsteinjoshi May 11, 2015 1:54 PM Flag

    RDHL is an extreme Low Float Stock means this Stock will explode on good news .

    Shares Out: 9.94 Million

    source : CNBC

    Top Institutional Holders

    Migdal Insurance ...3.8M

    Ben-Asher (Dror) ...2.7M

    OrbiMed ...605.8K

    Broadfin ...251.5K

    Candriam ...71.3K

    Goldman Sachs ...29.0K

  • This Low Float Stock has definitely the Potential to be the next Multi Billion Dollar Company .RDHL is one of the most Undervalued and Attractive Stock in the US Biotech Sector .GL

    Results from Phase 3 of Blockbuster Candidate RHB 105 (H. pylori ) coming IN JUNE

    Results from Phase 3 of Bekinda (gastroenteritis and gastritis) in 2H 2015

    EU Approval for Rizaport (Mirgaine) expected for 2H 2015

    EU Approval for Bekinda (oncology support) expected for 2H 2015

    Redhill (RDHL)

    MarketCap: $147 Million
    Cash: $32.6 Million

    Shares Out: 9.94 Million

    RHB-105: Top-line results from the first Phase III H. pylori eradication study- expected mid-end of June 2015 .Market Size: U.S. market is estimated at approximately $1-1.5 billion*

    BEKINDA™ (RHB-102): Feedback from UK MHRA regarding European marketing application for oncology support- H2/2015.Market Size: Worldwide market for serotonin (5-HT3) receptor inhibitors is estimated at $900 million**

    RIZAPORT™ (RHB-103): Feedback from Germany's BfArM regarding the European marketing application for migraines- H2/2015.The target market for RIZAPORT™, estimated at approximately $870 million*

    RIZAPORT™ (RHB-103): A new PDUFA date expected from the FDA for previously filed NDA- H2/2015

    BEKINDA™ (RHB-102): Top-line results from the Phase III study in acute gastroenteritis and gastritis- H2/2015.Worldwide potential market could exceed $650 million annually*

    RHB-104: Top-line interim results from Phase IIa study for Multiple Sclerosis- H2/2015.Market Size: Worldwide market of over $14 billion*

    Sentiment: Strong Buy

NURO
0.8291+0.0491(+6.29%)Jul 30 3:59 PMEDT